You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華檢醫療(01931.HK)年度純利升10.0%至1.75億元 末期息每股5.284港仙
格隆匯 03-20 18:20

格隆匯3月20日丨華檢醫療(01931.HK)公佈,截至2021年12月31日止年度,集團實現收益人民幣27.31億元,同比增長12.5%。有關增長主要是由於終端客户對體外診斷("IVD")產品的需求恢復,這是由於新型冠狀病毒疫情的影響減小,令醫院的營運逐步自COVID-19的爆發中恢復,給集團IVD產品分銷業務的銷售能力帶來積極影響。

期內,母公司擁有人應占溢利為1.75億元,同比增長10.0%。與截至2020年12月31日止年度相比,集團於報吿期間的溢利增長4.6%。該增長主要歸因於(i)收益恢復;(ii)毛利率增加;及(iii)並無截至2020年12月31日止年度的購股權開支人民幣1790.6萬元。上述各項因素部分被報吿期間有關根據於2020年5月19日採納的股份獎勵計劃以股份支付之僱員報酬福利之開支人民幣3855.5萬元所抵銷。

公司董事建議從公司股份儲備中的股份溢價賬撥資向股東派付截至2021年12月31日止年度的末期股息每股5.284港仙,惟須待股東於應屆股東周年大會上通過普通決議案批准。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account